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Abstract.  In culture, vascular smooth muscle ceils 
(SMC) grow in a "hill-and-valley" (multilayered) pat- 
tern of organization. We have studied the growth, be- 
havioral organization, and biosynthetic phenotype of 
rat aortic SMC exposed to purified platelet-derived 
growth regulatory molecules. We show that multi- 
layered growth is not a constitutive feature of cultured 
SMC, and that beta-type transforming growth factor 
(TGF-13) is the primary determinant of multilayered 
growth and the hill-and-valley pattern of organization 
diagnostic for SMC in culture. TGF-I~ inhibited, in a 
dose-dependent manner, the serum- or platelet-derived 
growth factor-mediated proliferation of these cells in 
two-dimensional culture, but only when cells were 
plated at subconliuent densities. The ability of TGF-[~ 
to inhibit SMC growth was inversely correlated to 
plating cell density. When SMC were plated at 
monolayer density (5  x  104 cells/cm  2) to allow maxi- 
mal cell-to-cell contact, TGF-[I potentiated cell 
growth. This differential response of SMC to TGF-[~ 
may contribute to the hill-and-valley pattern of organi- 
zation.  Unlike its effect on other cell types, TGF-I3 did 
not enhance the synthesis of fibronectin or its incorpo- 
ration into the extracellular matrix. However, the syn- 
thesis of a number of other secreted proteins was al- 
tered by TGF-13 treatment. SMC treated with TGF-13 
for 4 or 8 h  secreted markedly enhanced amounts of 
an Mr 38,000-D  protein doublet whose synthesis is 
known to be increased by heparin (another inhibitor of 
SMC growth), suggesting metabolic similarities be- 
tween heparin- and TGF-13-mediated  SMC growth 
inhibition. The data suggest that TGF-13 may play an 
important and complex regulatory role in SMC prolif- 
eration and organization during development and after 
vascular injury. 
U 
'NSCHEDULED proliferation of vascular smooth mus- 
cle cells (SMC)' is an important component of the 
atherogenic process (25) and a major factor in the 
failure of a significant number of vascular r~onstructions 
(7, 31). Our understanding  of the factors controlling  SMC 
growth derives, in large part, from studies of cultured cells. 
SMC proliferation in vitro can be stimulated by a variety of 
serum-derived growth factors,  most notably  the platelet- 
derived growth factor (PDGF) (24). SMC growth can be in- 
hibited by heparin-like molecules (4, 8) or by transforming 
growth factor-beta (TGF-I~), a multifunctional  peptide (re- 
cently reviewed by Sporn et al.  [27]) present in significant 
amounts in platelets (1, 2, 6, 22, 23) and synthesized by a va- 
riety of cells in culture (27). TGF-[3 may be an important 
regulatory factor for SMC in vivo given its high concentra- 
tion in platelets and the potential importance of  platelet prod- 
ucts in vascular pathologies. 
When isolated from the tunica media and cultured in se- 
rum, vascular  SMC are not strictly  contact-inhibited  and 
grow with a characteristic "hill-and-valley" morphology (5) 
("hills" consist of foci of  multilayered cells). In this report we 
show that multilayered growth is not a constitutive property 
1. Abbreviations  used in this paper: PDGF, platelet-defived growth factor; 
SMC, smooth muscle cell(s); "I'GF-I~, beta-type transforming growth factor. 
of tunica media-derived  cultured SMC, and present evidence 
that TGF-13 is the primary determinant of the hill-and-valley 
growth pattern of SMC in vitro. TGF-I3 exerts paradoxical 
control over SMC growth: as previously reported (2) and as 
shown herein, TGF-[I markedly inhibits the proliferation of 
sparsely plated SMC. At the same time, TGF-I3 specifies de- 
terminants that allow SMC to grow in multilayers, thus per- 
mitting cultures to reach markedly greater saturation densi- 
ties. This effect may be related to our finding that TGF-I3 can 
augment the growth of SMC at high cell density. TGF-I3 was 
also found to regulate the SMC biosynthetic phenotype and 
to induce synthesis of a previously described Mr 38,000-D 
protein whose secretion is markedly enhanced by heparin 
(13), another inhibitor of SMC growth (4, 8). Our data sug- 
gest that TGF-I3 may play an important role in directing the 
organizational,  proliferative,  and biosynthetic  behavior of 
SMC during development,  during angiogenesis,  and after 
injury. 
Materials and Methods 
Cell Culture 
Rat aortic SMC were grown from explants as described (14), and were sub- 
cultured in Waymouth's medium containing 10% FBS, 100 U/ml penicillin, 
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5 % CO2 atmosphere and were utilized in the third to sixth passage. Serum- 
free medium (12) was prepared as a 1:1 mixture of DMEM and F12 media 
supplemented with 0.1 mg/ml BSA and 5 pg/ml transferrin. Cultures were 
photographed on a Fluovert inverted microscope (E. Leitz, Wetzlar, Federal 
Republic of  Germany) using a ×4 or xl0 phase-contrast objective. For low- 
magnification photography, cells were stained with Coomassie Blue to aid 
visualization. 
Growth Factors 
PDGF was purchased from Bethesda Research Laboratories (Gaithersburg, 
MD). The PDGF was purified from fresh porcine platelets and was >90% 
pure by silver-stained  SDS-PAGE. The PDGF preparations contained <0.2 % 
TGF-[I. Porcine platelet TGF-13 was purchased  from R&D Systems, Inc. 
(Minneapolis,  MN),  and was shown to be >96%  pure by silver-stained 
SDS-PAGE, amino acid analysis, and NH2-terminus sequencing. The half- 
maximal activity of colony formation in soft agar (28) was determined to 
be 1 ng/ml. 
Cell Growth Assays 
Cell growth assays were performed in triplicate in  16-ram wells (12-well 
plates). Except where noted, cells were plated at 5  x  103 cells/cm  2 in 5 % 
FBS and  allowed to attach  and  spread  for 24  h before addition of test 
medium. At the time of harvest, medium was removed, cells were washed 
twice in PBS, and 1.0 ml of 0.4% trypsin/EDTA was added to each well. 
Cell  numbers  were  determined  electronically  on a  model  ZM  Coulter 
counter (Coulter Electronics, Inc., Hialeah, FL). All tissue culture chemi- 
cals were obtained from Gibco (Grand Island,  NY).  Where data are ex- 
pressed as percent inhibition of growth, values were derived according to 
this formula: % inhibition =  [1  -  (net growth of treated cells)/(net growth 
of control cells)] x  100, where the net growth of cells represents the differ- 
ence between the plating density and the final cell density. 
SDS-PAGE 
SMC were grown in 5% FBS in 35-mm diam tissue culture wells and were 
treated with  10 ng/ml TGF-13 as indicated. Metabolic labelings were per- 
formed by culturing cells for 2 h in serum-free medium lacking methionine 
in the presence of 50 pCi/ml [35S]methionine  (New England Nuclear, Bos- 
ton MA). Radiolabeled culture medium proteins were harvested into pro- 
tease inhibitors at 4°C to yield a final concentration of  25 mM EDTA, 1 mM 
N-ethylmaleimide, 45 pg/mi pepstatin, and 0.9 mM phenylmethylsulfonyl 
fluoride. Proteins were precipitated in 10% trichloroaeetic acid, dissolved 
in SDS-PAGE  sample buffer containing 50 mM dithiothreitol, and resolved 
on 6% or 10% polyacrylamide gels. Cell layer proteins were washed twice 
with PBS, lysed in 95"C sample buffer containing 50 mM dithiothreitol, and 
resolved on 6% or 10% polyacrylamide gels. Gels were fixed, dried,  and 
exposed to film at -70°C. The position of migration of fibronectin was de- 
termined by immunoprecipitation as described (15). Molecular mass esti- 
mates were derived from comparisons with the positions of migration of 
known molecular mass standards. 
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Figure 1.  Kinetics of SMC growth in 5 % FBS and in response to 
PDGE SMC were plated in 5% FBS at 5  x  103 cells/cm  2 in tripli- 
cate  16-mm wells and allowed to attach for 24 h. On day 0  (24 h 
after plating), cells were exposed to either (squares) fresh 5 % FBS 
or (circles) 0.5%  FBS supplemented with 10 ng/ml PDGF. Cells 
were fed fresh serum or PDGF on day 4  and cells were counted 
electronically at 2-d intervals. Note that SMC proliferating in re- 
sponse to PDGF achieve a  lower saturation density than do cells 
exposed to 5 %  FBS. 
Figure 2.  Morphologic appearance of SMC, at saturation density, 
after culture in PDGF or 5 % FBS. SMC were cultured as described 
in the legend to Fig.  1. On day 8, cultures were fixed in buffered 
3%  paraformaldehyde, stained with  Coomassie Blue,  and  pho- 
tographed. (a) SMC cultured in 0.5%  FBS supplemented with 10 
ng/ml PDGE (b) SMC cultured in 5 % FBS. Note that cultures ex- 
posed to PDGF reach monolayer saturation density and never ex- 
hibit multilayered growth or a ~hill-and-valley"  pattern of organiza- 
tion.  Cells grown in 5 %  FBS,  in contrast, are multilayered and 
present a hill-and-valley appearance typical of cultured SMC. Bar, 
200  ltm. 
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Growth Kinetics and Morphologic Organization of 
SMC Cultured in Serum or PDGF 
SMC proliferate in culture in response to FBS or in response 
to appropriate purified growth factors in the presence of ~main- 
tenance" levels of serum or plasma. Cells become quiescent 
if maintained  in  serum-free medium or  in  0.5%  FBS  for 
periods of 48-72 h (15, 16). However, in the additional pres- 
ence of 10 ng/ml PDGF (sufficient to elicit a substantial mito- 
genic  response  [16]),  proliferation  continues  albeit  at  a 
slower rate than for SMC maintained in FBS (Fig.  1). SMC 
grown in low serum and PDGF reached saturation densities 
of  1-2  x  105  cells/cm  2,  whereas  cells  grown  in  FBS 
reached threefold greater densities (5  x  105 cells/cm2). The 
morphologic appearance,  at confluency, of cultures grown 
under these conditions is presented in Fig. 2. As shown, cells 
cultured in FBS grew to overconfluence and organized into 
the  hill-and-valley pattern  characteristic  of vascular SMC 
in culture.  In contrast,  SMC maintained in 0.5%  FBS and 
PDGF reached only monolayer density and never exhibited 
multilayered growth. We conclude that multilayered growth 
is not a constitutive feature of vascular SMC in vitro, and that 
a  factor in serum, other than PDGF,  is the primary deter- 
minant of  this growth pattern. We have investigated the possi- 
bility that this determinant is TGF-I3. 
Effects of TGF-[3 on SMC Growth and Organization 
in Culture 
As shown previously (2), TGF-13 is a potent inhibitor of bo- 
vine aortic SMC growth in vitro, when given in concert with 
5 % FBS or in platelet-poor plasma supplemented with epi- 
dermal growth factor (EGF). We have used a 4-d cell number 
assay (described  in  Materials  and  Methods)  to  assess the 
effects of increasing amounts of TGF-[i on the proliferation 
of SMC prepared from the rat aorta. TGF-[i was found to be 
a  potent inhibitor of SMC proliferating in response to 5 % 
FBS (not shown) or 0.5% FBS supplemented with 10 ng/ml 
PDGF (Fig. 3), with a half-maximal effect observed at con- 
centrations <1  ng/ml.  A  maximal effect (>70%  inhibition) 
was seen at concentrations >110  ng/ml (Fig. 3). TGF-[i did not 
stimulate SMC proliferation when added alone (at 10 ng/ml) 
to cells maintained in 0.5%  FBS. 
The morphologic appearance of control and TGF-~-inhib- 
ited cells was determined, as part of our dose-response as- 
says (Fig. 3), on day 4.  As shown in Fig. 4 a, control cells 
(proliferating in response to PDGF alone) grew to a mono- 
layer and exhibited a "cobblestone" pattern of organization. 
In contrast, TGF-13-treated SMC organized into multilayered 
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Figure 3.  Effects of TGF-I3 on the proliferation  of SMC in vitro. 
SMC were plated in 5 % FBS at 5  x  103 cells/crn  2 in triplicate  16- 
ram wells and allowed to attach for 24 h. On day 0 (24 h after plat- 
ing), the cultures received 0.5 % FBS supplemented with 10 ng/ml 
PDGF alone or in concert with increasing amounts of TGF-[I. Cells 
were counted electronically on (squares) day 0 or (circles) day 4. 
Note that TGF-13-treated SMC show marked growth inhibition. 
Figure 4.  Morphologic  appearance of control and TGF-13-treated 
SMC. SMC were cultured as described in the legend to Fig.  1. On 
day  4,  cultures  were  fixed in  buffered  3%  paraformaldehyde, 
stained with Coomassie Blue, and photographed. (a) SMC cultured 
in 0.5 % FBS supplemented with 10 ng/ml PDGE (b) SMC cultured 
in 0.5% FBS  supplemented  with  10 ng/ml PDGF and  10 ng/ml 
TGF-[3. Note that TGF-13-treated  SMC, despite marked growth inhi- 
bition,  organized into multilayered aggregates ("hills") similar to 
those formed by SMC proliferating in response to 5 % FBS. Bar, 
200 ~tm. 
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growth by TGF-13 correlated with the ability of the cultures 
to form multilayers. 
Organizational Behavior of  SMC in Response to PDGF 
and TG  F-[3 
To further investigate the effects of TGF-I~ on multilayered 
growth of SMC,  we studied the organizational behavior of 
SMC maintained in a defined media (12), to eliminate possi- 
ble combinatorial effects of TGF-I~ with factors present in 
0.5%  FBS.  After  a  48-h  incubation  in  defined  medium, 
growth factors were added singly or in combination, and or- 
ganizational morphologies were examined at subconfluent or 
confluent  densities.  We  have  previously  shown  that  the 
defined medium used for these experiments is sufficient to 
support the mitogenic response of SMC to PDGF (16). 
As shown in Fig.  5,  SMC maintained in defined medium 
supplemented with PDGF and/or TGF-13 exhibited different 
organizational behaviors. After 4-8 d of serum-free culture, 
SMC appeared randomly dispersed on the culture surface; 
cells were moderately spread and ovoid rather than spindle- 
shaped (not  shown).  In contrast,  cells treated with TGF-13 
alone were not randomly distributed over the culture dish but 
instead were organized into "fascicles" of cells, often with the 
outermost cells aligned circumferentially around the perime- 
ter of the fascicle, enclosing an innermost group of randomly 
oriented  cells  (Fig.  5  a).  Typically, this type of organiza- 
tional  behavior was observed within 4  d  after addition  of 
TGF-13. Cells maintained in TGF-13 did not proliferate and 
did not reach confluent densities.  SMC treated with PDGF 
alone appeared, at sparse density, as randomly spread,  in- 
dividual cells with a more spindle-shaped morphology (not 
shown). At confluence, PDGF-treated cells exhibited a mono- 
layered, "cobblestone" pattern (Fig. 5 b), identical to that il- 
lustrated above (Fig.  2  a)  for SMC proliferating in PDGF 
Figure 5. Organizational behavior of SMC exposed to PDGF and/or TGF-13 under serum-free conditions.  SMC were plated in 5 % FBS 
at 5  X  103 cells/cm  ~ in 35-mm wells, allowed to attach for 24 h, then incubated in serum-free medium for 48 h (see text for details). Cells 
were then exposed to 10 ng/ml PDGF and/or  10 ng/ml TGF-13, as indicated, for 4-8 d. Cultures received fresh growth medium every 2 d. 
Cells were fixed as described and photographed after: (a) 8 d of treatment with TGF-13 alone; (b) 8 d of treatment with PDGF alone; (c) 
4 d of treatment with TGF-13  in concert with PDGF; and (dand e) 8 d of  treatment with TGF-fi in concert with PDGE Note (a) the organiza- 
tional behavior exhibited by SMC in response to TGF-13, (b) the monolayer growth pattern directed by PDGF alone, and (c-e) the mui- 
tilayered,  aggregatory growth patterns of SMC exposed to PDGF and TGF-I~ together. Bar, 200 ttm. 
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TGF-13 in  concert,  cells appeared  more elongate and  ag- 
gregated into multilayered foci, even at low density (Fig. 5, 
c and d). In confluent areas of the cultures, cells organized 
into distinct multilayered nodules and exhibited the hill-and- 
valley organization diagnostic for SMC in culture (Fig. 5 e). 
We therefore conclude, on the basis of  these data, that TGF-I3 
specifies the multilayered pattern of  growth of  cultured aortic 
SMC. 
Differential Effects of TGF-fl on SMC Proliferation 
To explain the apparent paradox between the ability of TGF-13 
to inhibit the growth of SMC cultures while simultaneously 
promoting the  formation of multilayered nodules,  we  hy- 
pothesized that TGF-13  may exert differential, density-depen- 
dent effects on SMC proliferation. To test this possibility, 
SMC were plated at l  x  103 ,5  x  103  ,1  x  104  , or5  x  104 
cells/cm  2 in either 16-mm wells (for growth studies) or in 
35-mm wells (for morphologic studies).  Cells were grown 
in 5 % FBS in the absence or presence of 10 ng/ml TGF-IL 
As presented in Fig. 6, TGF-13 was a potent inhibitor of the 
growth of sparsely plated SMC. However, as plating density 
increased, the efficacy of TGF-13 as a growth inhibitor was 
decreased.  The proliferation of cells plated  at  monolayer 
density (5  x  104 cells/cm  2) was augmented by TGF-I~. The 
morphologic appearance of SMC cultures after TGF-I$ treat- 
ment  under  these  conditions  is  also  presented  in  Fig.  6. 
These data,  which  imply a  selective ability  of TGF-13 to 
stimulate the growth of  cells already in aggregated conditions 
(in close contact with their neighbors), suggest a plausible 
mechanism by which TGF-13  may promote the hill-and-valley 
pattern of organization. 
Effects of TGF-~ on the SMC Biosynthetic Phenotype 
Previous studies that used other cell types (11, 23) have sug- 
gested that TGF-[I may exert certain of its growth-regulatory 
effects via enhancement of fibronectin synthesis. Fibronectin 
has  also been implicated in the formation of "nodules" in 
cultures of vascular SMC (3). These observations led us to 
investigate a possible role for fibronectin in the TGF-13-medi- 
ated effects described above. First, we used metabolic label- 
ing techniques to determine comparative levels of fibronectin 
synthesis in control and TGF-13-treated SMC. Control cells 
and cells treated with 10 ng/ml TGF-13  for 0--46 h were meta- 
bolically labeled for 2  h  with  [3SS]methionine  in the con- 
tinued presence of TGF-[~. Radiolabeled secreted and cell 
layer proteins were resolved by SDS-PAGE and visualized by 
autoradiography. No significant increase was noted in fibro- 
nectin synthesis (identified by specific immunoprecipitation) 
at any time point studied (Fig. 7). We also employed immu- 
nofluorescence techniques to detect possible differences in 
the distribution of fibronectin in control vs. TGF-13-treated 
SMC. SMC were cultured in 0.5 % FBS supplemented with 
10 ng/ml TGF-13, 10 ng/ml PDGF, or both factors for 72 h, 
then were fixed and stained with a goat antibody to rat fibro- 
nectin as previously described (14). No differences were ob- 
served in the distribution of fibronectin in the SMC matrix 
or on the cell surface under these three conditions. We pre- 
dict  that  the  TGF-13-mediated  morphologic  changes  de- 
scribed above are due to determinants other than fibronectin. 
Fig. 7 presents an SDS-PAGE analysis of the SMC biosyn- 
Figure 6. Differential effects  of  TGF-I)  on SMC growth as a function 
of cell density. SMC were plated in 5% FBS at the indicated densi- 
ties and allowed to attach for 24 h. On day 0 (24 h after plating), 
cell numbers were determined and cultures were exposed to either 
fresh 5% FBS or to 5% FBS supplemented with 10 ng/ml TGF-I~. 
Cell numbers were determined at day 3 and the percent inhibition 
or stimulation of growth was determined as described in Materials 
and Methods. As shown in the upper  panel, TGF-13 differentially 
inhibited or stimulated SMC proliferation as a function of cell den- 
sity. Cells plated at monolayer density (5  ×  104 cells/cm  2) were 
refractory to the growth-inhibitory effects of TGF-[~ and exhibited 
a marked stimulation of growth. (Lower  panel) Phase-contrast ap- 
pearance  of SMC  under  TGF-13-mediated growth-inhibitory or 
growth-promoting  conditions.  (a-c) SMC  plated  at  1  ×  104 
cells/cm2; (a) day 0; (b) day 3, 5% FBS; (c) day 3, 5% FBS sup- 
plemented with TGF-[$. (d-f) SMC plated at 5  ×  104 cells/cm2; 
(d) day 0; (e) day 3, 5% FBS; (f) day 3, 5% FBS supplemented 
with TGF-[I. Bar, 100 ~tm. 
thetic phenotype after treatment of cells with TGF-13 for 0, 
2, 4, 8, or 24 h. No differences in protein synthesis were de- 
tected in cell layer samples;  these data are not presented. 
Several differences in the relative production of secreted pro- 
teins were noted. We observed selective increases in proteins 
with M, 90,000,  38,000,  and  22,000  D  and  a  decrease in 
proteins with M, 92,000 and 55,000 D.  These proteins are 
of particular interest in view of the regulation of their pro- 
duction in other culture conditions. For example, PDGF treat- 
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SMC were plated in 5 % FBS and allowed to reach subconttuent 
densities in 35-mm wells. Fresh medium supplemented with 5 % 
FBS and 10 ng/ml TGF-I3  was added to experimental wells at appro- 
priam times. Cultures were subsequently metabolically labeled by 
incubation for 2  h  in  [35S]methionine-labeling  medium with or 
without fresh TGF-[3.  Labeled secreted proteins were harvested and 
resolved as described  in Materials and Methods. The indicated 
times represent the total length of  time cells were exposed to TGF-I~, 
including the 2-h labeling period.  Molecular masses of specific 
regulated proteins (xl03 D) are shown to the right. Note that TGF-[3 
did not stimulate synthesis of fibronectin (FN). SMC secreted in- 
creased  amounts  of  an  Mr  90,000-D protein  and  decreased 
amounts of proteins with Mr 92,000 and 55,000 D as a function of 
time of exposure to TGF-[~. SMC treated with TGF-[3 for 4 or 8 h 
secreted increased  amounts of an Mr 38,000-D protein  doublet 
whose synthesis is also regulated by heparin (13). Synthesis of an 
Mr 22,000-D protein was enhanced at 8 h but was unchanged at 
other time points examined. 
ment of quiescent SMC causes an increased synthesis of the 
Mr 92,000- and 55,000-D species and a decreased synthesis 
of the protein with Mr 90,000 D  (see reference 15, Figs.  3 
and 6). Although the identity and function of these proteins 
are unknown, their production appears to be antagonistically 
regulated by PDGF and TGF-13. 
Treatment of SMC with TGF-13  also resulted, at 4 and 8 h, 
in a  selective increase in the synthesis of an Mr 38,000-D 
protein. This protein exactly comigrates with an Mr 38,000-D 
protein doublet known to be induced by heparin (13), another 
inhibitor of SMC growth (4, 8). Synthesis of the Mr 38,000-D 
protein doublet was not increased above controls after 24 or 
48 h of exposure to TGF-13, despite the maintenance of other 
TGF-13-mediated biosynthetic changes at these time points. 
Discussion 
In culture, vascular SMC exhibit a characteristic "hill-and- 
valley" pattern of organization. This growth pattern has been 
extensively described in SMC cultures derived from a vari- 
ety of species (5, 9, 30) and is considered a diagnostic feature 
of these cells in culture (5). In this report we show that the 
ability to organize into multilayers is not a constitutive fea- 
ture of SMC in vitro. Rather, multilayered growth appears 
to be specified by the response of these cells to TGF-13, a re- 
cently described regulatory peptide that controls the growth 
and differentiation of a variety of cell types (10, 18,  19, 27). 
TGF-I~ is found in platelets (1, 2, 6, 22, 23) in concentrations 
roughly equivalent to that of PDGF (1). The effects of TGF-13 
on arterial SMC function may therefore be of considerable 
importance in vascular biology given the probable involve- 
ment of platelet products in atherogenesis, wound healing, 
and other vessel wall pathologies (25). Our data suggest that 
TGF-13 may regulate a number of SMC functions including 
proliferation (2), behavioral organization, and biosynthetic 
phenotype. 
The formation and maintenance of contact-inhibited mono- 
layer cultures has, until recently, been considered a feature 
exclusive (among vascular cells) to cultured endothelium. 
Although clonal variability in organizational behavior of  cul- 
tured SMC has been described (17), Walker et al. (29) have 
recently provided one example of a population of SMC that 
exhibits monolayered growth. In their studies, phenotypical- 
ly distinct SMC populations were cultured from the intima 
and media of carotid arteries after injury. Intimal-derived 
SMC secreted increased amounts of PDGF-like molecules, 
possessed fewer PDGF receptors, and exhibited a "cobble- 
stone" monolayer growth pattern  similar  to  that  of aortic 
media-derived SMC proliferating in response to PDGF alone 
(Figs. 2 and 4). Similar results have been described by Sei- 
fert et al. (26) for neonatal SMC. The data imply that an ad- 
ditional characteristic of neointimal or neonatal SMC pro- 
liferating in vivo may be a lack of responsiveness to TGF-13, 
a  possibility  which  is  currently being  investigated.  Mul- 
tilayered growth therefore does not appear to be a constitu- 
tive feature of cultured arterial SMC. Rather, the organiza- 
tional behavior of SMC in culture may vary according to the 
type of growth-regulatory molecules presented to the cells. 
The tendency to exhibit multilayered growth undoubtedly 
reflects an ability of TGF-I3 to differentially regulate SMC 
growth as well as an increased ability of SMC to interact, in 
a nonpolarized fashion, with all surfaces of its neighboring 
cells. This ability may be an important requisite for the for- 
mation of three-dimensional structures at appropriate time 
points during development or tissue repair. 
In other cell systems (11, 23), TGF-I3 appears to exert its 
growth-regulatory effects via stimulation of synthesis of fi- 
bronectin, a ubiquitous cell surface and extracellular matrix 
protein. SMC treated with TGF-I3 for up to 48 h showed no 
alteration in fibronectin synthesis or cell surface distribution 
of immunoreactive protein. Although our data cannot rule 
out subtle molecular alterations in fibronectin structure, we 
predict that the effects of TGF-13 on SMC growth and be- 
havioral organization are mediated by a determinant other 
than fibronectin. 
Other effects of TGF-I3 on the SMC biosynthetic pheno- 
type were observed in our studies. Of particular interest is 
the TGF-13-mediated increase in synthesis of a  secreted Mr 
38,000-D protein.  This protein appears  identical to an Mr 
38,000-D protein whose synthesis and secretion is markedly 
enhanced by treatment of rat SMC with heparin (13), a potent 
inhibitor of SMC  migration (14),  and proliferation (4,  8). 
The characteristics of regulation of this protein by heparin 
have been fully described (13). In contrast to the very rapid 
induction of secretion of this protein by heparin (13),  en- 
hanced production of the Mr 38,000-D protein w'.-s not ob- 
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data suggest a common metabolic relationship  between the 
mechanisms of heparin- and TGF-13-mediated growth inhi- 
bition. Finally, the Mr 38,000-D protein may relate to a pro- 
tein of similar size secreted by swine aortic SMC after for- 
mation of"nodules" (multilayered aggregates) in culture (20, 
21).  Our  data  predict  potentially  important  relationships 
among TGF-13, SMC growth inhibition in general, the forma- 
tion of multilayered aggregates ("nodules") of SMC, and ex- 
pression of an Mr 38,000-D secreted  protein. 
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